Continuing Nivolumab Beyond 2 Years in Stage IV RCC
In patients with stage IV renal cell carcinoma who have not achieved complete disease control by 2 years but tolerate nivolumab well, continuing therapy beyond 2 years is reasonable and supported by evidence, as durable responses can persist even after treatment discontinuation around the 24-month mark.
The Evidence on Treatment Duration
The most recent ESMO guidelines 1 explicitly state that "the benefit of continuing PD-1-targeted therapy beyond 2 years is uncertain." This reflects the design of major trials where PD-1 inhibitors were protocolized to stop at 2 years in combination regimens, while CheckMate 214 allowed nivolumab continuation to progression. The lack of certainty does not mean lack of benefit—it means we lack definitive comparative data.
Key Real-World Evidence
The highest quality recent study addressing this exact question 2 provides compelling data: among 95 mRCC patients who responded to immune checkpoint inhibitors and were treated for at least 21 months, elective discontinuation between 21-25 months (approximately 2 years) did not compromise outcomes compared to continuing therapy (adjusted HR 1.08,95% CI: 0.64-1.84, p=0.766). After discontinuation:
- 3-year PFS: 57.1%
- 3-year OS: 67.5%
- 3-year cancer-specific survival: 90.0%
Clinical Decision Algorithm
For patients at the 2-year mark, assess:
Response status:
- Complete response → Strong consideration for stopping (higher likelihood of durable benefit off therapy 2)
- Partial response with ongoing shrinkage → Continue therapy
- Stable disease → Either approach reasonable; favor continuation if well-tolerated
Metastatic pattern:
- Metachronous disease → Stopping more favorable 2
- Synchronous disease → Consider continuation
Toxicity burden:
- Minimal toxicity → Continue
- Cumulative immune-related adverse events → Favor stopping with close surveillance
Treatment setting:
Important Nuances
The "basic science" argument against continuing therapy is not supported by clinical evidence. Multiple case reports demonstrate sustained responses after nivolumab discontinuation 4, 5, 6, and some patients even experience continued tumor reduction post-discontinuation 7. This suggests immune memory effects persist beyond active treatment.
Treatment beyond progression may be beneficial in select cases 7: 13% of patients treated beyond RECIST progression achieved ≥30% tumor burden reduction, with acceptable safety profiles. However, this requires careful clinical judgment regarding true progression versus pseudoprogression.
Safety Considerations
Long-term safety data from CheckMate 9ER 8 with 5.6 years median follow-up shows no new deaths from study drug toxicity beyond earlier reports. Grade 3-4 treatment-related adverse events occurred in 67.8% with nivolumab-cabozantinib, but the incidence of treatment-related adverse events actually decreased after progression in patients continuing therapy 7 (59% post-progression vs 71% pre-progression).
Common Pitfalls to Avoid
- Don't automatically stop at 2 years if disease is actively responding and patient tolerates therapy well—the 2-year cutoff in trials was arbitrary, not biologically driven
- Don't continue indefinitely without reassessing benefit—if stable disease persists beyond 2 years without further improvement, stopping with close surveillance is reasonable
- Don't restart therapy at first sign of progression after stopping—some patients experience delayed responses or prolonged stability off therapy 2, 5, 6
The decision to continue or stop should prioritize the individual patient's response trajectory, toxicity profile, and disease characteristics rather than adhering rigidly to a 2-year cutoff.